NCT06602843 Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
| NCT ID | NCT06602843 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anhui Provincial Hospital |
| Condition | Esophageal Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
Eligibility Criteria
Inclusion Criteria: * Ages 18-75; * Radical operation for esophageal cancer; * Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation were performed, and the stage was pIIB-IVA (AJCC eighth edition staging criteria: T≥3 or N+). * More than or equal to 12 lymph nodes were surgically removed; * Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy; * Informed consent signed by patient or family member. Exclusion Criteria: * Less than 18 years old, more than 75 years old; * did not receive radical resection of esophageal cancer, including palliative resection; * Postoperative pathology showed non-esophageal squamous cell carcinoma; * After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB (AJCC eighth edition staging standard); e. Less than 12 lymph nodes were surgically removed; * Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy; * The patient or family member did not sign the informed consent.
Frequently Asked Questions
Who can join the NCT06602843 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Esophageal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06602843 currently recruiting?
Yes, NCT06602843 is actively recruiting participants. Visit ClinicalTrials.gov or contact Anhui Provincial Hospital to inquire about joining.
Where is the NCT06602843 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT06602843 clinical trial?
NCT06602843 is sponsored by Anhui Provincial Hospital. The trial plans to enroll 70 participants.